First author of publication | Number of participants (n) | Participants | Interventions | Outcomes | ||||
---|---|---|---|---|---|---|---|---|
Treatment (male) | Control 1 (male) | Control 2 (male) | Treatment | Control 1 | Control 2 | |||
Ahmad (2002) [27] | 28 | 10 (NA) | 10 (NA) | 8 (NA) | G-CSF 5 μg/kg/12 h, IV, 7 days or until ANC ≥ 10000 cells/mm3 | GM-CSF 4 μg/kg/12 h, IV, 7 days or until ANC ≥ 10000 cells/mm3 | Placebo | All-cause mortality; hospital stay duration |
Ahmed (2006) [28] | 60 | 30 (15) | 30 (16) |  | IgG 500 mg/kg/d, IV, 3 days | No intervention |  | All-cause mortality; hospital stay duration |
Akdag (2014) [29] | 102 | 51 (30) | 51 (31) |  | IgGAM 250 mg/kg/d, IV, 3 days | Placebo (saline) |  | All-cause mortality; hospital stay duration |
Aktas (2015) [30] | 56 | 33 (23) | 23 (17) |  | G-CSF 10 μg/kg/d, until ANC ≥ 1.0 × 109/L | No intervention |  | All-cause mortality |
Bedford Russell (2001) [31] | 28 | 13 (3) | 15 (4) |  | G-CSF 10 μg/kg/d, IV, maximum of 14 days | Placebo |  | All-cause mortality; mechanical ventilation days; ICU stay duration |
Bilgin (2001) [32] | 60 | 30 (17) | 30 (18) |  | GM-CSF 5 μg/kg/d, IH, 7 days | No intervention |  | All-cause mortality; hospital stay duration |
Borjianyazdi (2013) [33] | 46 | 23 (12) | 23 (14) |  | GCSF 10 μg/kg/d, IH, 5 days | Placebo (saline) |  | All-cause mortality; hospital stay duration |
Chaudhuri (2012) [34] | 78 | 39 (22) | 39 (24) |  | GCSF 10 μg/kg/d, IV, 3 days | Placebo (5% dextrose) |  | All-cause mortality |
Chen (1996) [35] | 56 | 28 (NA) | 28 (NA) |  | IgG 500 mg/kg, one dose | Placebo (0.9% sodium chloride) |  | All-cause mortality |
Christensen (1991) [36] | 22 | 11 (NA) | 11 (NA) |  | IgG 750 mg/kg, IV, one dose | Placebo (albumin) |  | All-cause mortality |
Drossou-Agakidou (1998) [37] | 35 | 19 (NA) | 16 (NA) |  | G-CSF 10 lg/kg/d, IH, 3 days | No intervention |  | All-cause mortality |
Drossou-Agakidou (2002) [38] | 56 | 17 (8) | 19 (9) | 20 (13) | GM-CSF 5 mcg/kg/d, IV, 4 days | G-CSF 10 mcg/kg/d, IV, 4 days | Placebo (saline) | All-cause mortality; hospital stay duration; mechanical ventilation days |
El-Ganzoury (2012) [39] | 60 | 30 (15) | 30 (16) |  | G-CSF 10 μg/kg/d, IV, 3 days | No intervention |  | All-cause mortality; hospital stay duration; mechanical ventilation days |
Erdem (1993) [40] | 44 | 20 (NA) | 24 (NA) |  | IgGAM 5 ml/kg/d, IV, 3 days | No intervention |  | All-cause mortality |
Gathwala (2012) [18] | 40 | 20 (11) | 20 (13) |  | G-CSF 10 mg/kg/d, IV, 5 days | No intervention |  | All-cause mortality; hospital stay duration |
Gunes (2006) [41] | 88 | 33 (18) | 33 (12) |  | IgG 500 mg/kg, IV | No intervention |  | All-cause mortality |
Haque (1988) [42] | 60 | 30 (20) | 30 (24) |  | IgGAM 5 mL/kg/d, IV, 4 days | Placebo (10% dextrose) |  | All-cause mortality |
Haque (1995) [43] | 195 | 65 (NA) | 65 (NA) | 65 (NA) | IgG 250 mg/kg/d, IV, 4 days | IgGAM, pentaglobin 250 mg/kg/d, IV, 4 days | no intervention | All-cause mortality |
INIS Collaborative Group (2011) [17] | 3493 | 1759 (NA) | 1734(NA) |  | IgG 500 mg/kg/48 h, IV, 2 doses | Placebo (saline/ albumin solution) |  | All-cause mortality; hospital stay duration |
Kucukoduk (2002) [44] | 40 | 20 (12) | 20 (11) |  | G CSF 5 μg/kg/d, IV, 3 days | Placebo (physiological serum) |  | All-cause mortality; ICU stay duration |
Mancilla-Ramirez (1992) [45] | 37 | 19 (NA) | 18 (NA) |  | IgG 500 mg/kg, IV, one dose | Placebo (maltose) |  | All-cause mortality |
Miura (2000) [46] | 44 | 22 (9) | 22 (14) |  | G-CSF 10 μg/kg/d, IV, 3 days | Placebo |  | All-cause mortality |
Samatha (1997) [47] | 60 | 30 (NA) | 30 (NA) |  | IgGAM 5 mL/kg/d, 3 days | No intervention |  | All-cause mortality; hospital stay duration |
Schibler (1998) [48] | 20 | 10 (6) | 10 (7) |  | G-CSF 10 μg/kg/d, IV, 3 days | Placebo |  | All-cause mortality |
Shenoi (1999) [49] | 57 | 25 (18) | 25 (20) | 7 (5) | IgG 1 g/kg, IV, 3 days | Placebo (0.15% saline in 10% dextrose) | no intervention | All-cause mortality; hospital stay duration; mechanical ventilation days |
Sidiropoulos (1981) [50] | 82 | 41 (NA) | 41 (NA) |  | IgG preterm infants: 0.5 g/d, 6 days; term infants: 1.0 g/d, 6 days | No intervention |  | All-cause mortality |
Weisman (1992) [51] | 31 | 14 (7) | 17 (10) |  | IgG 500 mg/kg, IV | Placebo (albumin) |  | All-cause mortality; hospital stay duration |